The liver’s own immune cells may be inadvertently driving the scarring that leads to organ failure. Chronic liver injury triggers a vicious cycle: resident stromal cells turn into scar-producing myofibroblasts, while tissue-resident T cells (TRM) normally stationed in the liver for immune defence may start pumping out pro-fibrogenic signals that accelerate this process. Exactly how these two cell types talk to each other—and whether that conversation shifts from protective to destructive as disease progresses—remains unknown. This project will map that cellular crosstalk, asking whether TRM cells actively push stromal cells toward fibrosis, and whether blocking that communication could halt or reverse scarring. Liver fibrosis is a major unmet clinical need; no approved drugs directly target the scarring process itself. If this fundamental science reveals the molecular handshake between TRM and stromal cells, it could identify new drug targets for therapies that promote fibrosis regression rather than just managing symptoms. Similar discoveries about immune–stromal interactions in other organs have already opened paths to anti-fibrotic treatments—this work aims to do the same for the liver.
View original technical description
The liver has an extraordinary capacity to regenerate, yet chronic insult can lead to uncontrolled tissue repair, scarring (fibrosis) and ultimately organ failure. Profibrogenic mediators that accumulate upon injury activate resident stromal cells to differentiate into myofibroblasts aberrantly secreting extracellular matrix (ECM) ? these myofibroblasts aThe liver has an extraordinary capacity to regenerate, yet chronic insult can lead to uncontrolled tissue repair, scarring (fibrosis) and ultimately organ failure. Pro-fibrogenic mediators that accumulate upon injury activate resident stromal cells to differentiate into myofibroblasts aberrantly secrete extracellular matrix (ECM) - these myofibroblasts are the 'master mediators' of fibrosis. The ability of specialised T cells that reside permanently in tissues, tissue resident T cells (TRM), to provide efficient local immunity has ignited interest in harnessing their power for immunotherapy, however emerging data suggest they may interact with stromal cells, and may contribute to tissue damage. The interplay between hepatic TRM and stromal cells, in health and disease, remains unknown. Therefore, I hypothesise that TRM interact and communicate with stromal cells to cross-regulate cell distribution, survival, function and fibrogenic potential to exacerbate (or limit) liver disease. Moreover, I propose that the retention of 'poised' T cells and their in-situ localisation is influence by bidirectional signalling with the underlying stromal cells. In addition, as fibrosis progresses, I propose the function of TRM becomes dysregulated favouring the production of pro-fibrogenic mediators, that in turn enhance myofibroblast differentiation. Collectively, by understanding the cellular crosstalk between ECM-producing stromal cells and TRM in the liver this research aims to reveal new anti-fibrotic approaches for clinical translation to promote fibrosis regression and limit ECM deposition - an urgent unmet clinical need.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know